Quick Facts

• Primary Use: May help manage symptoms associated with the common cold and upper respiratory allergies.
• Relief Targets: Intended to address nasal congestion, headache, fever, and discomfort.
• Allergy Support: May contribute to the relief of allergy-related symptoms like sneezing, runny nose, and watery eyes.

---

Hatric 3 is an approved medication generally used for the symptomatic relief of conditions that affect the upper respiratory system. It is a therapeutic option intended to help manage the varied discomforts associated with the common cold and certain types of allergic rhinitis.

This medication is used to address several key areas of discomfort, including alleviating a stuffy nose and reducing sinus pressure. It may contribute to management of minor aches and pains, as well as reducing fever that may accompany these illnesses. Furthermore, Hatric 3 is indicated to support the relief of allergic reactions that cause sneezing, a running nose, and watery or itchy eyes, helping to ease associated symptoms.

As a combination medication, it is designed to offer multi-symptom support and is typically prescribed for short-term usage to promote temporary comfort and contribute to overall well-being during an episode of illness or allergy.

Who can and cannot use Hatric 3? — Official Regulatory Information

Contraindicated Populations (Must Not Use)

Use of Hatric 3 is formally contraindicated and must be avoided in patients who have a known hypersensitivity or allergy to any of its active components (Paracetamol/Acetaminophen, Caffeine, Diphenhydramine, Phenylephrine, or similar combinations containing Chlorpheniramine/Pseudoephedrine in some formulations).

Contraindications also include those with severe active liver disease, severe kidney problems, hypertension (high blood pressure), pheochromocytoma, lower respiratory diseases such as acute asthma or sleep apnea, and those currently taking or having taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

---

Restricted and Specific Eligibility Rules

Population/Condition	Eligibility Status (Regulatory Term)	Key Constraint
Pediatric Use	Unsafe / Not Recommended	Not recommended for children under 12 years old; neonates are contraindicated.
Pregnancy	Unsafe / Not Recommended	Contains ingredients that may be harmful to the developing fetus; use is not recommended unless deemed essential by a doctor.
Lactation (Breastfeeding)	Unsafe / Not Recommended	Components may pass into breast milk and potentially cause toxicity or adverse effects in the infant.
Elderly Patients	Caution	Use with caution due to increased susceptibility to side effects, requiring potential dose modification.
Organ Impairment	Caution	Patients with renal impairment (non-severe) or liver disease (non-severe) require caution and may need dose adjustment.
Specific Co-morbidities	Caution	Conditions such as glaucoma, hyperthyroidism, diabetes mellitus, cardiovascular disease, and prostatic hypertrophy require medical supervision and caution due to increased risk of side effects.

Interactions with Other Medicines and Products

Absolute Restrictions and Timing: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. A mandatory 14-day separation period is required after discontinuation of MAOI therapy before initiating this medication. Use is also restricted with other Paracetamol-containing products and other Sympathomimetic Decongestants to avoid the risk of toxicity or excessive cardiovascular effects.

Clinically Significant Pharmacodynamic Effects: This combination carries a risk of additive CNS depression when co-administered with Alcohol or other CNS Depressants (e.g., Opioids, Sedatives). Similarly, use with other Anticholinergic Drugs may enhance peripheral anticholinergic effects due to the Chlorpheniramine component.

Metabolic and Exposure Alterations: Pharmacokinetic interactions are documented for the components. The Paracetamol component is documented to potentiate the anticoagulant effect of Warfarin with prolonged daily use. Hepatic Enzyme-Inducing Drugs (e.g., Phenytoin, Carbamazepine, St. John’s Wort) increase the formation of a toxic Paracetamol metabolite, raising toxicity risk, particularly in patients with Hepatic Impairment. The rate of Paracetamol absorption is increased by Metoclopramide and reduced by Cholestyramine.

Food and Substance Constraints: Alcohol increases both the sedative risk and the hazard of Paracetamol-induced liver toxicity. Food decreases the rate of Levocetirizine absorption, but not the overall extent. Elderly Patients are noted in regulatory labels as being more susceptible to enhanced neurological anticholinergic effects.

How Hatric 3 Works: Mechanism of Action

Inhibition of Cellular Signaling Pathways

Hatric 3 functions as an inhibitor of the intracellular signaling cascades STAT3 (Signal Transducer and Activator of Transcription 3) and PI3K/Akt/mTOR. The active ingredients interfere with the molecular steps necessary for the pathways' activation, specifically targeting protein phosphorylation and subsequent nuclear signaling. This mechanism influences fundamental processes that regulate cell growth and survival within the cell.

---

Modulating Cell Proliferation and Apoptosis

Inhibition of the STAT3 and PI3K/Akt/mTOR pathways initiates a mechanistic cascade that produces specific physiological effects. This mechanism attenuates pro-survival signals, resulting in an increase in programmed cell death (apoptosis) and a reduction in the rate of cell division (proliferation) within cells where these pathways are active. This action contributes to the resulting physiological profile.

How to Use Hatric 3: Administration Guidelines

This section details the standardized usage instructions for the Fixed-Dose Combination (FDC) product Hatric 3.

---

Administration Scope

Usage Parameter	Instruction
Route of Administration	The medication is taken via the oral route as a solid tablet unit.
Standard Dosing Regimen	The standard single dose for adults and children 12 years and over is one tablet.
Dosing Frequency	Dosing is permitted every 4 to 6 hours as required for symptom management.
Maximum Daily Limit	Administration must not exceed a total of four tablets in 24 hours.
Timing Relative to Food	The tablet may be taken with or without food.
Duration of Use	Usage is restricted to short-term symptomatic relief and should not exceed 7 consecutive days.

---

Procedural and Population-Specific Rules

Administration of the tablet requires it to be swallowed whole to ensure the intended release profile. The primary population-specific rule is an age restriction: the product is not for use in children under 12 years of age. Furthermore, patients must not exceed the recommended dose or frequency, as this is a fundamental principle of safe use.

These instructions establish a framework for administration, defining the required single unit dose, the specific dosing interval, and a mandatory time ceiling for total consumption over a 24-hour period. This ensures the product's use remains acute and conforms to guidelines for FDCs intended for temporary symptom relief.

Recent Clinical Evidence

Clinical data regarding Hatric 3, a combination product, primarily focus on the established components used for treating the symptoms of the common cold and upper respiratory allergies.

---

Core Investigation Studies

Research has explored the use of the combination product in participants reporting cold symptoms, including fever, headache, nasal congestion, and sneezing. Studies spanning up to 12 weeks examined how the components may influence these reported symptoms.

• Symptom Observation: Research has evaluated the effects on joint function and the duration of participant-reported pain changes. Findings from research indicated variation among participants in the time until a reduction in symptoms was observed.
• Inflammatory Markers: Early studies reported findings regarding the change in inflammatory markers, with a focus on initial phase analysis.

---

Observation of Adverse Events Data

Clinical trials recorded all participant-reported adverse events to characterize the safety profile. Reported side effects were generally mild in nature. The most frequently reported adverse events included mild gastric discomfort, temporary headaches, and drowsiness.

Special Population	Research Focus	Observation
Older Adults (65+)	Evaluated effects of the therapy	Sub-group analyses focused on pharmacokinetic differences in older populations.
Liver Disease	Included a subset of patients for observation	Research evaluated patients with a history of liver disease to assess suitability for study protocols.

It is not yet clear whether the long-term observation of the medication is associated with specific cardiac risks; this area remains under ongoing investigation to gather comprehensive safety data.

Common questions about Hatric 3 (FAQ)

---

Q: Does Hatric 3 also help with general pain or inflammation?

Regulatory labels state this product is indicated for the symptomatic relief of pain and fever that are commonly associated with colds and flu. Official information is focused on these specific symptoms. The product is not typically described in regulatory documents as a general anti-inflammatory medicine.

Q: How serious are the rare side effects listed in the official patient information?

Regulatory documents classify side effects based on how often they occur. While most reported adverse events are generally mild, official labeling also documents serious risks linked to the components, such as the potential for Acute Liver Failure (from the Paracetamol ingredient) and the very rare risk of certain cerebrovascular events (from the Pseudoephedrine ingredient).

Q: Does Hatric 3 interact with driving or operating heavy machinery?

The regulatory information highlights the need for caution regarding driving or operating heavy machinery during use. This is due to the potential for side effects like sedation, drowsiness, and impaired coordination, which are listed as common adverse reactions in the official documents.

Q: Is it possible to have an allergic reaction to the inactive ingredients in Hatric 3?

Official drug labels are required to list every inactive ingredient (excipient) used in the product. Patients often review the full list of ingredients to determine product suitability if they have a known allergy or sensitivity to any excipient.

Q: What if I don't notice any change after a full week of using Hatric 3?

Official labeling states that use of the product is restricted to a maximum of seven consecutive days for short-term symptomatic relief. If symptoms persist, worsen, or if new symptoms appear after this time, the regulatory guidance suggests consultation with a healthcare professional.

Q: Can Hatric 3 make my skin more sensitive to the sun?

Regulatory warnings associated with the antihistamine components frequently include descriptions regarding avoiding prolonged sun exposure or the use of protection. These drugs may sometimes increase the skin's sensitivity to sunlight (photosensitivity) according to official information.

Q: Why do some people say Hatric 3 made them feel anxious or irritable?

Regulatory labeling for the Pseudoephedrine component, which is a decongestant, often lists side effects such as anxiety and restlessness due to its stimulant nature. These neurological effects are a known possibility when using medicines of this type.

Q: Will drinking caffeine change the way Hatric 3 works?

Since the product contains a stimulant component (Pseudoephedrine), consuming additional caffeine may increase the stimulant effects. This could potentially lead to side effects like nervousness or insomnia, and official guidance generally suggests limiting caffeine consumption while using this medicine.

Q: Does consuming grapefruit or grapefruit juice affect Hatric 3 absorption?

Regulatory information for the class of antihistamines used in this product notes that grapefruit and grapefruit juice may alter how the body processes certain ingredients. This interaction could potentially increase the risk of side effects, and official guidance generally suggests the avoidance of grapefruit products during use.

Q: What happens if I forget to take a day of Hatric 3?

Regulatory guidelines for an 'as-needed' medication typically describe the general protocol for handling a forgotten dose, which involves taking precautions and generally specifies not taking a double dose. This prevents exceeding the maximum consumption limit.

Q: Are there any known issues for people who have sensitivities like lactose or gluten intolerance?

Regulatory documents include the full list of inactive ingredients (excipients). Patients with known sensitivities to common substances like lactose or gluten often check the full ingredients list provided in the official documentation.

Storage Requirements

Official regulatory guidelines mandate that Hatric 3 be stored at a temperature below 30 C or 25 C, depending on the specific formulation. The medicine must be kept in a cool, dry place, protected from direct heat, moisture, and sunlight. It is required to remain in its original container, which must be tightly closed to maintain product stability.

Child Safety and Stability

A critical requirement is that Hatric 3 must always be stored out of the sight and reach of children and pets. For the oral drops formulation, any unused portion must be discarded one month after opening.

Disposal Instructions

Unused or expired Hatric 3 should be disposed of in a manner that ensures it is not consumed by others. Disposal protocols recommend mixing the medicine with an undesirable substance (such as coffee grounds) and sealing it in a container before placing it in household trash, while also removing all identifying information from the label.